![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Cyclerion Therapeutics Inc | NASDAQ:CYCN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.34 | 2.25 | 5.00 | 0 | 09:00:00 |
Massachusetts
|
83-1895370
|
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer
Identification No.)
|
245 First Street, 18th Floor
Cambridge, Massachusetts
|
02142
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
Smaller reporting company ☒
|
Emerging growth company ☒
|
Item 3. |
Incorporation of Documents by Reference.
|
Item 8.
|
Exhibits.
|
Exhibit
Number
|
Description
|
|
Restated Articles of Organization of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.1 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615).
|
||
Amended and Restated Bylaws of Cyclerion Therapeutics, Inc. (incorporated by reference to Exhibit 4.2 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615).
|
||
Cyclerion Therapeutics, Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.3 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615).
|
||
Cyclerion Therapeutics, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 4.4 to Registration Statement on Form S-8 filed on March 29, 2019) (File No. 333-230615).
|
||
Opinion of Foley Hoag LLP (filed herewith)
|
||
Consent of Ernst & Young, LLP (filed herewith)
|
||
Consent of Foley Hoag LLP (included in the opinion filed as Exhibit 5.1).
|
||
Power of Attorney (included in the signature page to this Registration Statement)
|
||
Filing Fee Table (filed herewith)
|
CYCLERION THERAPEUTICS, INC.
|
|||
By:
|
/s/ Anjeza Gjino
|
||
Name:
|
Anjeza Gjino
|
||
Title:
|
Chief Financial Officer
|
Signature
|
Title
|
Date
|
||
/s/ Peter M. Hecht
|
Chief Executive Officer (Principal Executive Officer) and Director
|
August 10, 2022
|
||
Peter M. Hecht
|
||||
/s/ Anjeza Gjino
|
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)
|
August 10, 2022
|
||
Anjeza Gjino
|
||||
/s/ George Conrades
|
Director
|
August 10, 2022
|
||
George Conrades
|
||||
/s/ Errol De Souza
|
Director
|
August 10, 2022
|
||
Errol De Souza
|
||||
/s/ Marsha Fanucci
|
Director
|
August 10, 2022
|
||
Marsha Fanucci
|
||||
/s/ Steven E. Hyman
|
Director
|
August 10, 2022
|
||
Steven E. Hyman
|
||||
/s/ Ole Isacson
|
Director
|
August 10, 2022
|
||
Ole Isacson
|
||||
/s/ Stephanie Lovell
|
Director
|
August 10, 2022
|
||
Stephanie Lovell
|
||||
/s/ Terrance McGuire
|
Director
|
August 10, 2022
|
||
Terrance McGuire
|
||||
/s/ Michael Mendelsohn
|
Director
|
August 10, 2022
|
||
Michael Mendelsohn
|
1 Year Cyclerion Therapeutics Chart |
1 Month Cyclerion Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions